Allogeneic T cells Transduced with an Anti-CD19 Chimeric Antigen Receptor

这项试验是少数几项专门专注于将抗CD19 CAR T细胞应用于同种异体移植环境的CAR试验之一。这项试验意义重大，因为与大多数抗CD19嵌合抗原受体的试验不同，它不包括化疗，因此它对抗CD19 CAR T细胞的活性进行了纯粹的评估。我们将继续招募更多的患者参加这项试验。我们正在获得关于每个患者的毒性和成功治疗的预测因素的重要信息。一篇涵盖本试验的论文（Brudno等人）2016年发表在《临床肿瘤学杂志》上。该项目现在专注于测试被称为干记忆T细胞（Ttscm）的分化程度较低的T细胞，这些细胞被抗CD19 CAR转导。在这项工作中，我们目前正在与另一位ETIB研究者Luca Gattinoni合作，开发一种同种异体抗CD19 CAR干记忆T细胞的给药方法。Tscm细胞的细胞生产过程已经到位，我们已经在这项临床试验中用抗CD19 CAR Tscm细胞治疗了前5名患者。1例急性淋巴细胞白血病患者在输注Tscm抗CD19 CAR T细胞后获得完全缓解，目前正在进行中。另一例淋巴瘤患者获得部分缓解。另外3名患者的恶性肿瘤没有客观缓解。我们将继续治疗更多的患者，并对本临床试验的患者样本进行广泛的相关研究

This trial is one of few CAR trials exclusively focused on applying anti-CD19 CAR T cells to the allogeneic transplantation setting. This trial is significant because unlike most trials of anti-CD19 chimeric antigen receptors, it does not include chemotherapy, so it gives a pure assessment of the activity of the anti-CD19 CAR T cells. We continue recruit more patients for this trial. We are obtaining important information on toxicity and predictors of successful therapy with each patient. A paper covering this trial (Brudno et al.) was published in the Journal of Clinical Oncology in 2016. The project is now focused on testing less-differentiated T cells called stem memory T cells (Ttscm) transduced with an anti-CD19 CAR. In this effort, we are currently collaborating with another ETIB Investigator, Luca Gattinoni, in developing a process for administering allogeneic anti-CD19 CAR stem memory T cells. The cell production process for Tscm cells has been put in place, and we have treated the first 5 patients with anti-CD19 CAR Tscm cells on this clinical trial. A patient, with acute lymphoid leukemia, obtained a complete remission after infusion of Tscm anti-CD19 CAR T cells that is ongoing. Another patient with lymphoma obtained a partial remission. the other 3 patients did not have an objective response of their malignancies. We will continue to treat more patients and to carry out extensive correlative studies of patient samples from this clinical trial